Market News

Cronos Group Inc. is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 Management Cease Trade Orders . On November 9, 2021, the Company announced that it applied for a management cease trade order with the applicable securities regulatory authorities in Canada on the basis that the Company would be unable to file its Quarterly Report on Form ...

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos Group" or the "Company") is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 Management Cease Trade Orders (" NP 12-203 ").

On November 9, 2021, the Company announced that it applied for a management cease trade order (" MCTO ") with the applicable securities regulatory authorities in Canada on the basis that the Company would be unable to file its Quarterly Report on Form 10-Q for the period ended September 30, 2021 (the " Form 10-Q ") with the U.S. Securities and Exchange Commission (the " SEC "), together with its corresponding quarterly filings in Canada (collectively, the " Required Filings "), by the applicable filing deadlines (the " Original Announcement "). The MCTO was issued on November 16, 2021 and restricts all trading in securities of the Company, whether direct or indirect, by the Chief Executive Officer and Chief Financial Officer of the Company until two full business days following the filing of the Required Filings and the MCTO has been revoked. The MCTO does not affect the ability of other shareholders of the Company to trade their securities.

The Company confirms that since the date of the Original Announcement: (i) there has been no material change to the information set out in the Original Announcement that has not been generally disclosed; (ii) there has been no failure by the Company in fulfilling its stated intentions with respect to satisfying the provisions of the alternative information guidelines set out in NP 12-203; (iii) there has not been any other specified default by the Company under NP 12-203; and (iv) there is no other material information concerning the affairs of the Company that has not been generally disclosed.

The Company's management continues to work diligently to complete the Required Filings. The Company confirms it will continue to satisfy the provisions of the alternative information guidelines set out in NP 12-203 so long as it remains in default of the requirement to file the Required Filings.

About Cronos Group Inc.
Cronos Group is an innovative global cannabinoid company with international production and distribution across five continents. Cronos Group is committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos Group is building an iconic brand portfolio. Cronos Group's portfolio includes PEACE NATURALS™, a global wellness platform, two adult-use brands, COVE™ and Spinach™, and three U.S. hemp-derived CBD brands, Lord Jones™, Happy Dance™ and PEACE+™. For more information about Cronos Group and its brands, please visit: thecronosgroup.com.

Forward-Looking Statements
This news release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and U.S. securities laws (collectively, "Forward-looking Statements"). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. Some of the Forward-looking Statements contained in this press release include the duration of the MCTO and the Company's ability to complete the Required Filings and continue to satisfy the information guidelines set out in NP 12-203. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies that may cause the actual filing time of the Required Filings to be materially different from the estimated future filing time or prevent us from complying with the requirements of NP 12-203 and the Forward-looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2021 and the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2021, each of which have been filed on SEDAR and EDGAR and can be accessed at www.sedar.com and www.sec.gov/edgar, respectively. Any Forward-looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos Group disclaims any obligation to update or revise any Forward-looking Statement. Readers are cautioned not to put undue reliance on any Forward-looking Statement.

Cronos Group Contact
Shayne Laidlaw
Investor Relations
Tel: (416) 504-0004
Investor.relations@thecronosgroup.com


News Provided by GlobeNewswire via QuoteMedia

business meeting evaluating financial results

Cannabis Weekly Round-Up: Organigram Results Improve, Ascend Ready for Lawsuit

A Canadian cannabis producer beat estimates in its latest financial results, and experts believe it may be showing signs of achieving profitability.

Also this week, Ascend Wellness Holdings (AWH) (CSE:AAWH.U,OTCQX:AAWH) revealed it will be taking its dispute with MedMen Enterprises (CSE:MMEN,OTCQX:MMNFF) to court.

Keep reading to find out more cannabis highlights from the past five days.

Keep reading... Show less
Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product

Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product

The trial evaluates Numinus' first trademarked product and patent-pending production process

 Numinus Wellness Inc. ("Numinus") (TSX: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to announce that it has formally submitted the clinical trial application ("CTA") to Health Canada for its Phase 1 study, HOPE, on a naturally derived Psilocybe extract formulation, NBIO-01. This milestone further progresses and solidifies Numinus' long-standing work on developing safe and effective psychedelic products out of its Health Canada-licensed research facility, Numinus Bioscience.

Keep reading... Show less
Avicanna Enters Master Supply Agreement with Chilean Pharmaceutical Pioneer Knop Laboratorios S.A.

Avicanna Enters Master Supply Agreement with Chilean Pharmaceutical Pioneer Knop Laboratorios S.A.

Expansion and fortification of relationship since 2020 with established pharmaceutical company in Chile

Supply of Avicanna's active pharmaceutical ingredients for existing commercial and pipeline of pharmaceutical products in South America

Keep reading... Show less
Numinus Announces Cancellation and Rescheduling of Annual General Meeting of Shareholders

Numinus Announces Cancellation and Rescheduling of Annual General Meeting of Shareholders

Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announced today that its annual general meeting of shareholders (the "AGM"), which was originally scheduled to be held on Friday, January 21, 2022 has been cancelled and rescheduled to be held on February 28 2022. The Company's Board of Directors determined that it would be in the best interests of the Company to reschedule the AGM for a variety of reasons, including a change to at least one resolution.

Further details on the AGM will be contained in a new Notice of Meeting and Management Information Circular that will be mailed to shareholders of the Company and filed on SEDAR.

Keep reading... Show less

IIROC Trade Resumption - CL

Trading resumes in:

Company: Cresco Labs Inc.

Keep reading... Show less

IIROC Trading Halt - CL

The following issues have been halted by IIROC:

Company: Cresco Labs Inc.

Keep reading... Show less

Latest Press Releases

Related News

×